Literature DB >> 19168727

NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart.

Ping Zhang1, Mingxiao Hou, Yunfang Li, Xin Xu, Michel Barsoum, Yingjie Chen, Robert J Bache.   

Abstract

Increased reactive oxygen species (ROS) produced by the failing heart can react with nitric oxide (NO), thereby decreasing NO bioavailability. This study tested the hypothesis that increased ROS generation contributes to coronary endothelial dysfunction in the failing heart. Congestive heart failure (CHF) was produced in six dogs by ventricular pacing at 240 beats/min for 4 wk. Studies were performed at rest and during treadmill exercise under control conditions and after treatment with the NADPH oxidase inhibitor and antioxidant apocynin (4 mg/kg iv). Apocynin caused no significant changes in heart rate, aortic pressure, left ventricular (LV) systolic pressure, LV end-diastolic pressure, or maximum rate of LV pressure increase at rest or during exercise in normal or CHF dogs. Apocynin caused no change in coronary blood flow (CBF) in normal dogs but increased CBF at rest and during exercise in animals with CHF (P < 0.05). Intracoronary ACh caused dose-dependent increases of CBF that were blunted in CHF. Apocynin had no effect on the response to ACh in normal dogs but augmented the response to ACh in CHF dogs (P < 0.05). The oxidative stress markers nitrotyrosine and 4-hydroxy-2-nonenal were significantly greater in failing than in normal myocardium. Furthermore, coelenterazine chemiluminescence for O(2)(-) was more than twice normal in failing myocardium, and this difference was abolished by apocynin. Western blot analysis of myocardial lysates demonstrated that the p47(phox) and p22(phox) subunits of NADPH were significantly increased in the failing hearts, while real-time PCR demonstrated that Nox2 mRNA was significantly increased. The data indicate that increased ROS generation in the failing heart is associated with coronary endothelial dysfunction and suggest that NADPH oxidase may contribute to this abnormality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168727      PMCID: PMC2660225          DOI: 10.1152/ajpheart.00519.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  40 in total

1.  Expression of phagocyte NADPH oxidase components in human endothelial cells.

Authors:  S A Jones; V B O'Donnell; J D Wood; J P Broughton; E J Hughes; O T Jones
Journal:  Am J Physiol       Date:  1996-10

2.  Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols.

Authors:  David K Johnson; Kurt J Schillinger; David M Kwait; Chambers V Hughes; Erin J McNamara; Fauod Ishmael; Robert W O'Donnell; Ming-Mei Chang; Michael G Hogg; Jonathan S Dordick; Lakshmi Santhanam; Linda M Ziegler; James A Holland
Journal:  Endothelium       Date:  2002

3.  Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.

Authors:  Tomoyuki Takayama; Atsuyuki Wada; Takayoshi Tsutamoto; Masato Ohnishi; Masanori Fujii; Takahiro Isono; Minoru Horie
Journal:  Circ J       Date:  2004-11       Impact factor: 2.993

4.  Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction.

Authors:  P A J Krijnen; C Meischl; C E Hack; C J L M Meijer; C A Visser; D Roos; H W M Niessen
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

5.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.

Authors:  K K Griendling; C A Minieri; J D Ollerenshaw; R W Alexander
Journal:  Circ Res       Date:  1994-06       Impact factor: 17.367

6.  Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase.

Authors:  G C Brown; C E Cooper
Journal:  FEBS Lett       Date:  1994-12-19       Impact factor: 4.124

7.  Coronary microvascular endothelial stunning after acute pressure overload in the conscious dog is caused by oxidant processes: the role of angiotensin II type 1 receptor and NAD(P)H oxidase.

Authors:  Shintaro Kinugawa; Heiner Post; Pawel M Kaminski; Xiaoping Zhang; Xiaobin Xu; Harer Huang; Fabio A Recchia; Manuel Ochoa; Michael S Wolin; Gabor Kaley; Thomas H Hintze
Journal:  Circulation       Date:  2003-12-01       Impact factor: 29.690

8.  High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase.

Authors:  Zoltan Ungvari; Anna Csiszar; An Huang; Pawel M Kaminski; Michael S Wolin; Akos Koller
Journal:  Circulation       Date:  2003-07-21       Impact factor: 29.690

9.  Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol.

Authors:  J Stolk; T J Hiltermann; J H Dijkman; A J Verhoeven
Journal:  Am J Respir Cell Mol Biol       Date:  1994-07       Impact factor: 6.914

10.  Inhibition of nitric oxide production aggravates myocardial hypoperfusion during exercise in the presence of a coronary artery stenosis.

Authors:  D J Duncker; R J Bache
Journal:  Circ Res       Date:  1994-04       Impact factor: 17.367

View more
  12 in total

1.  Family-based association studies for next-generation sequencing.

Authors:  Yun Zhu; Momiao Xiong
Journal:  Am J Hum Genet       Date:  2012-06-08       Impact factor: 11.025

2.  Increased NADPH oxidase-derived superoxide is involved in the neuronal cell death induced by hypoxia-ischemia in neonatal hippocampal slice cultures.

Authors:  Qing Lu; Mark S Wainwright; Valerie A Harris; Saurabh Aggarwal; Yali Hou; Thomas Rau; David J Poulsen; Stephen M Black
Journal:  Free Radic Biol Med       Date:  2012-06-19       Impact factor: 7.376

3.  Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.

Authors:  Weijuan Li; Yaoqi Chen; Songhai Li; Xiaopeng Guo; Wenping Zhou; Qiutang Zeng; Yuhua Liao; Yumiao Wei
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

4.  NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure.

Authors:  Yu Liu; He Huang; Wenfang Xia; Yanhong Tang; Haitao Li; Congxin Huang
Journal:  Mol Cell Biochem       Date:  2010-06-22       Impact factor: 3.396

5.  Predictors of oxidative stress in heart failure patients with Cheyne-Stokes respiration.

Authors:  Ana C Krieger; Daniel Green; Muriel T Cruz; Frank Modersitzki; Gita Yitta; Sanja Jelic; Doris S Tse; Steven P Sedlis
Journal:  Sleep Breath       Date:  2010-11-20       Impact factor: 2.816

6.  Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213.

Authors:  Yu-si Cheng; De-zai Dai; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2009-07-13       Impact factor: 6.150

Review 7.  The TNF-α/sphingosine-1-phosphate signaling axis drives myogenic responsiveness in heart failure.

Authors:  Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Vasc Res       Date:  2013-04-16       Impact factor: 1.934

8.  Carnosine protects cardiac myocytes against lipid peroxidation products.

Authors:  Jingjing Zhao; Dheeraj Kumar Posa; Vijay Kumar; David Hoetker; Amit Kumar; Smirthy Ganesan; Daniel W Riggs; Aruni Bhatnagar; Michael F Wempe; Shahid P Baba
Journal:  Amino Acids       Date:  2018-11-17       Impact factor: 3.520

9.  Cardiac inflammation after local irradiation is influenced by the kallikrein-kinin system.

Authors:  Vijayalakshmi Sridharan; Preeti Tripathi; Sunil K Sharma; Eduardo G Moros; Peter M Corry; Benjamin J Lieblong; Elena Kaschina; Thomas Unger; Christa Thöne-Reineke; Martin Hauer-Jensen; Marjan Boerma
Journal:  Cancer Res       Date:  2012-08-03       Impact factor: 12.701

Review 10.  Mechanisms and clinical implications of endothelium-dependent vasomotor dysfunction in coronary microvasculature.

Authors:  Sharif A Sabe; Jun Feng; Frank W Sellke; M Ruhul Abid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-25       Impact factor: 5.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.